ChristopherCarrollSmith

AVROBIO not a good value despite great clinical trial results

NASDAQ:AVRO   AVROBIO INC
AVROBIO got a good pop today from very positive Phase 2 clinical trial results from its kidney drug. Unquestionably the news was good; the drug shows strong efficacy and no adverse events.

However, this was only a Phase 2 trial so there's a long way still to go in the approval process. Meanwhile, the company is losing money and is rated as an overvalued and financially unhealthy company by analytics firms.

AVRO has some support from historical volume in the range from 15.00-15.50, so it could get a short-term bounce from that level, but I wouldn't play this one long-term.

Check out my free market news and education podcast, Wall Street Petting Zoo, on YouTube or your favorite podcast app! On Podbean at https://wallstreetpettingzoo.podbean.com/ and on Twitter at https://twitter.com/WSPZoo.

Comments

Great view, keep it up!
Reply
Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing Refer a friend House Rules Help Center Website & Broker Solutions Widgets Charting Solutions Lightweight Charting Library Blog & News Twitter
Profile Profile Settings Account and Billing Referred friends Coins My Support Tickets Help Center Private Messages Chat Sign Out